Gharibo, Mecide
Bristol-Myers Squibb (United States)
3 papers on CoChat
Most cited papers
- Verified
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet
Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research
Cited by 854
- Verified
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Carpio, C., Bouabdallah, R., Ysebaert, L., Sancho, J.-M., Salles, G., Cordoba, R., Pinto, A., Gharibo, M., Rasco, D., Panizo, C., et al. (2020) · Blood
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 72
- Verified
Completed induction phase analysis of MAGNIFY: phase 3b study of lenalidomide + rituximab (R 2) followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma
Lansigan, F., Andorsky, D. J., Coleman, M., Yacoub, A., Melear, J., Fanning, S., Kolibaba, K. S., Reynolds, C. M., Nowakowski, G. S., Gharibo, M., et al. (2021) · Blood
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 14
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free